The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

Atlas Venture and Bain Capital Life Sciences are making their next bet in the buzzy obesity field, launching a new startup ...

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

Dr. Eileen Barr, an obesity physician in East Setauket, said the new drugs are being released at ... found that New York's obesity rate rose from 29.1% in 2021 to 30.1% in 2022 before falling ...

The U.S. obesity rate is about 40 percent, according to a 2021-2023 survey of about ... WATCH: The many ways new weight loss drugs could transform the economy The overall obesity rate appeared ...

23, 2024 — With Medicare now covering semaglutide for people with obesity and cardiovascular ... Patients Prescribed GLP-1 RA Medications Sep. 13, 2024 — A new study identified key factors ...

The U.S. obesity rate is about 40%, according to a 2021-2023 survey ... s too soon to know whether new treatments for obesity, including blockbuster weight-loss drugs such as Wegovy and Zepbound ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

The average workplace health insurance plan costs more than $25,000 amid rising prices and expensive weight-loss drugs such ...